- Eli Lilly (LLY) said the U.S. FDA has approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen.
- Patients, with a valid prescription, opting for self-pay through LillyDirect, can receive all doses of Zepbound in a KwikPen or single
Lilly’s Zepbound gets FDA label expansion approval for KwikPen
